B cells have a significant role in the positive immune response affecting the outcome of cancer. Tabby Therapeutics is developing first-in-class novel engineered B cells (EBC) for tumor immunotherapy.
By introducing engineered B cell receptors (BCR) directed against tumor specific targets, they can exert multiple anti-tumor effects leveraging B cell unique capabilities to orchestrate humoral, cellular, adaptive and innate immune responses. Tabby’s EBCs offer a novel living and evolving tuned-medicine for the treatment of solid tumors.